USPTO Examiner MONSHIPOURI MARYAM - Art Unit 1651

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19005540PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLEDecember 2024June 2025Allow510NoNo
18885661POLYMERASE MUTANT AND APPLICATIONS THEREOFSeptember 2024February 2025Allow510YesNo
18656340HUMAN ALPHA-GALACTOSIDASE VARIANTSMay 2024November 2024Allow600YesNo
18654723PROCESS FOR PRODUCTION OF A SOLUBLE AND INSOLUBLE COLLAGEN PRODUCT FROM MAMMALIAN DERMIS TISSUEMay 2024August 2024Allow411YesNo
18634776OLIGOSACCHARIDE DEBRANCHING ENZYME MUTANT AND USE THEREOF IN GLUCOSE MOTHER LIQUORApril 2024April 2025Allow1200YesNo
18587665Methods of Adding Polymers to Ribonucleic AcidsFebruary 2024February 2025Allow1201YesNo
18682024METHOD FOR PRODUCING A RECOMBINANT BACTERIAL COLLAGEN-LIKE PROTEIN (CLP)February 2024September 2024Allow710YesNo
18424277ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOMEJanuary 2024June 2025Abandon1711NoNo
18391409PDE5A DESTABILIZING DOMAINSDecember 2023April 2025Abandon1510NoNo
18544275FUSION CONSTRUCTS AS PROTEIN OVER-EXPRESSION VECTORSDecember 2023April 2025Allow1610YesNo
18540631PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILEDecember 2023March 2025Abandon1511NoNo
18530082ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATESDecember 2023April 2025Allow1611YesNo
18526930COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTIONDecember 2023April 2025Allow1611YesNo
18519620POLYMERASE ENZYME FROM 9�NNovember 2023March 2025Abandon1610NoNo
18493395ATTENUATED GLUTAMINE SYNTHETASE AS A SELECTION MARKEROctober 2023January 2025Abandon1401NoNo
18286782PROCESS TO PRODUCE MONO-RHAMNOLIPIDSOctober 2023March 2025Allow1740YesNo
18461604OLIGOPEPTIDE WITH LIPID-LOWERING ACTIVITY, PREPARATION METHOD AND APPLICATION THEREOFSeptember 2023June 2024Allow1010YesNo
18462237ENGINEERED AMYLASE VARIANTSSeptember 2023April 2024Allow700YesNo
18455342METHODS FOR OPTIMIZING GAS UTILIZATIONAugust 2023May 2025Abandon2010NoNo
18448856RNA POLYMERASE VARIANTSAugust 2023August 2024Allow1201YesNo
18446758CARBON SEQUESTRATION IN SOILS WITH PRODUCTION OF CHEMICAL PRODUCTSAugust 2023September 2024Allow1311YesNo
18226833Method for Modifying Polyester by Swelling Agent Combined with CutinaseJuly 2023January 2024Allow610YesNo
18354044METHODS FOR CO-PRODUCING ERYTHRITOL AND ARABINOSE BY USING XYLOSE MOTHER LIQUORJuly 2023October 2023Allow200NoNo
18267874ALLULOSE EPIMERASE VARIANT WITH EXCELLENT THERMAL STABILITY, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR ALLULOSE USING SAMEJune 2023October 2024Allow1600NoNo
18323090CELLMay 2023September 2024Allow1610NoNo
18316222Genus Hydrogenophilus Bacterium TransformantMay 2023August 2024Allow1611YesNo
18316224Genus Hydrogenophilus Bacterium TransformantMay 2023August 2024Allow1611YesNo
18310744TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21May 2023September 2024Allow1731YesNo
18308336CRISPR/CAS FUSION PROTEINS AND SYSTEMSApril 2023February 2025Abandon2211NoNo
18132279Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the SameApril 2023February 2024Allow1000NoNo
18130560COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID INTERACTION REPORTERSApril 2023July 2024Allow1521YesNo
18182481METHOD FOR PREPARING XYLOGLUCAN-OLIGOSACCHARIDESMarch 2023September 2024Abandon1810NoNo
18112968METHODS AND STRAINFebruary 2023November 2024Allow2111YesNo
18163496Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOFFebruary 2023May 2024Allow1621YesNo
18018303PROCESSES FOR REDUCING STEAM CONSUMPTION AND IMPROVING PROCESS CARBON BALANCE IN BIOMASS CONVERSION TO SUGARS, BIOCHEMICALS, BIOFUELS, AND/OR BIOMATERIALSJanuary 2023March 2024Allow1311YesNo
18158339PENICILLIN-G ACYLASESJanuary 2023April 2024Allow1501YesNo
18155541METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM, ARDS, AND ACUTE LUNG INJURY USING BETA-GLUCOCEREBROSIDASEJanuary 2023August 2024Abandon1910NoNo
18150018LUCIFERASE-BASED THERMAL SHIFT ASSAYSJanuary 2023September 2023Allow900YesNo
18148284PROTEIN COMPLEX BASED ON DNA ENZYMES OF E FAMILY OF ESCHERICHIA COLI AND APPLICATION THEREOF IN ARTIFICIAL PROTEIN SCAFFOLDSDecember 2022December 2023Allow1121YesNo
18080631MICROBIAL STEM CELL TECHNOLOGYDecember 2022June 2025Allow3020YesNo
18000246METHOD FOR IMPROVING PRODUCTIVITY OF 2'-FUCOSYLLACTOSE THROUGH ENZYMATIC TREATMENTNovember 2022May 2023Allow500YesNo
18050224XANTHAN LYASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAMEOctober 2022August 2024Abandon2111NoNo
17960099SIMULTANEOUS ENZYMATIC CELLULOSE HYDROLYSIS AND PRODUCT SEPARATION IN A RADIAL-FLOW MEMBRANE BIOREACTOROctober 2022June 2023Allow810NoNo
17936076PROCESSES FOR PRODUCING A FERMENTATION PRODUCTSeptember 2022December 2024Allow2630YesNo
17942774RECOMBINANT HOST CELL WITH ALTERED MEMBRANE LIPID COMPOSITIONSeptember 2022May 2024Allow2020YesNo
17822789SELF-STERILIZING FABRICS INCORPORATING ANTI-VIRAL COLD-ACTIVE PROTEASESAugust 2022May 2025Abandon3310NoNo
17905064MODIFIED POLYPEPTIDE HAVING MANNANASE ACTIVITYAugust 2022January 2025Allow2900NoNo
17904213GLYCOMINIMIZED BACTERIAL HOST CELLSAugust 2022July 2024Abandon2322YesNo
17817413COMPOSITIONS AND METHODS FOR ENHANCED PRODUCTION OF ENDURACIDIN IN A GENETICALLY ENGINEERED STRAIN OF STREPTOMYCES FUNGICIDICUSAugust 2022August 2023Allow1200YesNo
17759261HMO PRODUCTIONJuly 2022March 2025Allow3200YesNo
17813088EXPRESSION VECTORJuly 2022April 2025Allow3350YesNo
17812460ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOFJuly 2022January 2024Abandon1910NoNo
17811051CELL-FREE GLYCOPROTEIN SYNTHESIS (CFGPS) IN PROKARYOTIC CELL LYSATES ENRICHED WITH COMPONENTS FOR GLYCOSYLATIONJuly 2022June 2024Allow2330YesNo
17857624MUTANT THIOESTERASESJuly 2022April 2024Allow2101YesNo
17852907E. COLI STRAINS HAVING AN OXIDATIVE CYTOPLASMJune 2022January 2025Allow3121YesNo
17788620ALLULOSE EPIMERASE VARIANT, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING ALLULOSE USING THE SAMEJune 2022January 2023Allow600YesNo
17787558METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTORJune 2022May 2025Allow3500YesNo
17786885BINDING PROTEINS FOR THE ENZYME ACID ALPHA GLUCOSIDASE (GAA) AND USES THEREOFJune 2022January 2025Allow3100YesNo
17839233FUSION PROTEINS AND METHODS FOR SITE-DIRECTED GENOME EDITINGJune 2022January 2024Allow1910NoNo
17837660EFFICIENT PRODUCT CLEAVAGE IN TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDESJune 2022October 2023Allow1610YesNo
17828131COMPOSITIONS AND METHODS FOR TREATING FARBER DISEASEMay 2022November 2023Abandon1710NoNo
17824643GENETICALLY ENCODED FLUORESCENT SENSORS FOR DETECTING LIGAND BIAS AND INTRACELLULAR SIGNALING THROUGH cAMP PATHWAYSMay 2022June 2024Allow2530NoNo
17749796PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILEMay 2022November 2023Allow1821YesNo
17743716Genetically Engineered Strain for Producing Porcine Myoglobin and Food-grade Fermentation and Purification ThereofMay 2022March 2023Allow1011YesNo
17727990ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOFApril 2022January 2025Allow3330YesNo
17724712PRODUCTION OF BACTERIOCINSApril 2022January 2024Abandon2101NoNo
17724390ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATESApril 2022September 2023Allow1601NoNo
17699927AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASEMarch 2022January 2025Allow3430YesNo
17653441DPO4 POLYMERASE VARIANTSMarch 2022February 2024Allow2411YesNo
17677670INSULIN DERIVATIVES WITH A TERMINAL LPXT MOTIFFebruary 2022October 2023Abandon2001NoNo
17676099MEMBRANE BIOREACTOR FOR SIMULTANEOUS ENZYMATIC CELLULOSE HYDROLYSIS AND PRODUCT SEPARATIONFebruary 2022September 2022Allow710YesNo
17636720Blumea Balsamifera Monoterpene Synthase BBTPS3 And Related Biological Materials Thereof and Use ThereofFebruary 2022May 2025Allow3910YesNo
17670738T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORSFebruary 2022June 2023Allow1610NoNo
17665265ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOMEFebruary 2022February 2024Abandon2511NoNo
17550495POLYPEPTIDE HAVING LUCIFERASE ACTIVITYDecember 2021August 2023Allow2011YesNo
17548677ENGINEERED GLUCOSYLTRANSFERASESDecember 2021November 2023Abandon2310NoNo
17547836CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOFDecember 2021September 2024Allow3331YesNo
17454060MOLECULAR SWITCHESNovember 2021May 2024Allow3021YesNo
17453476SYSTEM AND METHOD FOR GENERATING BUBBLES IN A VESSELNovember 2021July 2024Allow3331YesNo
17474708PRODUCTION OF CANNABINOIDS IN YEASTSeptember 2021November 2023Allow2601YesNo
17474226ALPHA-AMYLASE VARIANTS HAVING IMPROVED PERFORMANCE AND STABILITYSeptember 2021October 2023Abandon2501NoNo
17469386CRISPR-CAS SYSTEM FOR CLOSTRIDIUM GENOME ENGINEERING AND RECOMBINANT STRAINS PRODUCED THEREOFSeptember 2021April 2025Allow4311YesNo
17467318SELF-STERILIZING FABRICS INCORPORATING ANTI-VIRAL COLD-ACTIVE PROTEASESSeptember 2021July 2022Allow1111YesNo
17460147ENGINEERED AMYLASE VARIANTSAugust 2021May 2023Allow2011NoNo
17408328N- AND C-TERMINAL TANDEM TAG SYSTEM FOR PURIFICATIONAugust 2021September 2024Allow3721YesNo
17445047POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAMEAugust 2021July 2023Allow2310YesNo
17395282ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OILAugust 2021January 2024Allow2921YesNo
17374262LIGASE FUSION PROTEINS AND APPLICATION THEREOFJuly 2021July 2022Allow1221YesNo
17350078POLYMERASE ENZYME FROM 9�NJune 2021August 2023Allow2610YesNo
17350662RNA POLYMERASE VARIANTSJune 2021June 2023Allow2401YesNo
17342928CHROMATOGRAPHIC METHOD FOR COLLECTING BLOOD COAGULATION FACTOR VII WITH HIGH YIELDJune 2021January 2024Allow3120YesNo
17336975Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the SameJune 2021January 2023Allow1900YesNo
17327313ULTRAMARINE FLUORESCENT PROTEIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF PROTEIN SUNSCREEN AGENTMay 2021June 2023Allow2511YesNo
17323737PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES IN MICROBIAL HOSTS WITH ENGINEERED IMPORT / EXPORTMay 2021March 2024Allow3311YesNo
17320866METHOD OF MAKING RECOMBINANT SILK AND SILK-AMYLOID HYBRID PROTEINS USING BACTERIAMay 2021March 2025Allow4621YesNo
17321049MODIFIED ACTIVIN AMay 2021February 2025Allow4510NoNo
17313675MICROORGANISMS AND METHODS FOR PRODUCING 2-PYRONE-4,6-DICARBOXYLIC ACID AND OTHER COMPOUNDSMay 2021January 2024Allow3221YesNo
17307609SYSTEMS INCLUDING SIMULATED MOVING BED SEPARATORS FOR HIGH PURITY FRUCTOSE PRODUCTION AND RELATED METHODSMay 2021April 2024Allow3511YesNo
17244190COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTIONApril 2021October 2023Allow3021YesYes
17244180COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTIONApril 2021November 2023Allow3120NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONSHIPOURI, MARYAM.

Strategic Value of Filing an Appeal

Total Appeal Filings
10
Allowed After Appeal Filing
4
(40.0%)
Not Allowed After Appeal Filing
6
(60.0%)
Filing Benefit Percentile
62.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner MONSHIPOURI, MARYAM - Prosecution Strategy Guide

Executive Summary

Examiner MONSHIPOURI, MARYAM works in Art Unit 1651 and has examined 507 patent applications in our dataset. With an allowance rate of 91.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.

Allowance Patterns

Examiner MONSHIPOURI, MARYAM's allowance rate of 91.1% places them in the 74% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by MONSHIPOURI, MARYAM receive 1.06 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MONSHIPOURI, MARYAM is 21 months. This places the examiner in the 83% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +19.9% benefit to allowance rate for applications examined by MONSHIPOURI, MARYAM. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.2% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 51.6% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.9% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 21.1% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.